Digene DNA Pap Approval Anticipation Boosts Stock 45% In February
This article was originally published in The Gray Sheet
Executive Summary
Investor expectations for imminent approval of Digene's HPV DNA Pap test as a primary screen for cervical cancer appeared to drive a 44.6% increase in the company's stock price to $16.59 in February
You may also be interested in...
TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy
TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy
Expansion Of HPV “High Risk” Type Group Entails “Tradeoff” – NEJM Article
Five HPV DNA types previously classified as "low-risk" or "undetermined risk" should be added to the 13 types already linked to a "high" cervical cancer risk, according to a study by Nubia Munoz, MD, International Agency for Research on Cancer, Lyons, France, et al